

**RECEIVED**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

JUL 17 2002

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**Docket Number:
1662/54902**TECH CENTER 1600/2900**Application Number
10/045,510Filing Date
October 19, 2001Examiner
not yet assignedArt Unit
1621Invention Title
**CRYSTALLINE VENLAFAXINE BASE AND
NOVEL POLYMORPHS OF VENLAFAXINE
HYDROCHLORIDE, PROCESSES FOR
PREPARING THEREOF**Inventors
DOLITZKY et al.COPY OF PAPERS
ORIGINALLY FILEDAddress to:
Assistant Commissioner for Patents
Washington D.C. 20231I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner of Patents and Trademarks,
Washington, D.C. 20231 onDate: 7/4/02 Reg. No. 46,877

Signature: _____

Siu K. Lo

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the reference listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed for charging purposes.

Dated: _____

By: _____

Siu K. Lo (Reg. No. 46,877)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 01662/54902	SERIAL NO. 10/045,510
	APPLICANT DOLITZKY et al.	
	FILING DATE October 19, 2001	GROUP 1621



U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUB- CLASS	FILING DATE*

RECEIVED

* - if pertinent

JUL 17 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Daniel Vega et al. , 1-[2-(1-Hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl]dimethyl-ammonium chloride (venlafaxine hydrochloride), Acta Crystallographica Section C Crystal Structure Communications, 2000, C56, pp. 1009-1010

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**COPY OF PAPERS
ORIGINALLY FILED**